Dynavax(US:DVAX)2025-11-05 21:30Financial Performance - HEPLISAV-B net product revenue reached $90 million in Q3'25, a 13% year-over-year increase compared to $79 million in Q3'24[5, 81] - The company anticipates HEPLISAV-B net revenue to be between $315 million and $325 million for the full year 2025[78] - Adjusted EBITDA for FY 2025 is expected to be at least $80 million, revised up from the previous guidance of at least $75 million[9, 79, 85] - Cash, cash equivalents, and marketable securities totaled approximately $648 million as of September 30, 2025[7, 83] - Total revenues for Q3'25 were $949 million, an 18% increase from $806 million in Q3'24[77] Market Position and Strategy - HEPLISAV-B's total U S market share reached 46% at the end of Q3'25, compared to 44% in Q3'24[5, 81] - The U S adult Hepatitis B vaccine market is projected to peak at over $900 million by 2030, with HEPLISAV-B expected to achieve at least 60% of the total U S market share[5, 25] - The company is focused on maximizing HEPLISAV-B's commercial potential, advancing its diversified vaccine pipeline, and continuing a balanced capital allocation strategy[12] Pipeline Development - The company's plague vaccine program received approximately $14 million in additional funding from the U S DoD, bringing the total funding to approximately $44 million through the first half of 2027[11, 87] - Dynavax entered into an exclusive license agreement for Vaxart's oral COVID-19 vaccine candidate, involving a $25 million upfront payment and a $5 million equity investment[68] - The global shingles vaccine market size was approximately $42 billion in 2024[33]